Altaris has completed its acquisition of the Life Sciences & Healthcare business from Clarivate, for undisclosed terms. LS&H will operate as an independent company under Altaris’ ownership, with Henry Levy continuing as chief executive. The business will be headquartered in Pennsylvania and will be rebranded in due course.\n\nLS&H provides AI-enabled data intelligence and decision-support tools for R&D and commercialization to the pharmaceutical, biotechnology and medical technology industries.
It has two business units: Cortellis, which serves customers across drug development, regulatory and safety use cases, and Decision Resources Group, which provides data-driven products and consulting services covering product commercialization and market access strategies.\n\nThe company has about 2,300 employees across 22 countries. Its global customer base includes the top 20 pharmaceutical companies and 18 of the top 20 medical technology companies. New York-based Altaris invests exclusively in healthcare and manages $10 billion of equity capital.
Since its inception in 2003, it has invested in more than 50 companies.\n\nJP Morgan Securities served as exclusive financial adviser and Kirkland & Ellis as legal counsel to Altaris. Morgan Stanley was financial adviser and Davis Polk & Wardwell legal adviser to Clarivate.
Source: PE Hub · Summarized by HeadlinesBriefing